FDA urges tighter warnings on antidepressants for suicide risk
The FDA orders makers of 10 SSRIs and related drugs to add stronger suicide-related warnings. The agency flags early therapy and dose changes as high risk times while stressing the link to underlying illness remains unclear. Adults and youths are covered as reanalysis probes past conclusions.